Mark Mascolini

Mark Mascolini has been writing about HIV and AIDS since the beginning of the epidemic. Peer-reviewed work he coauthored has appeared in JAIDS, Antiviral Therapy and the Journal of the International AIDS Society.

His work appears regularly on and the websites of the National AIDS Treatment Advocacy Project (NATAP), AVAC and the Center for AIDS, as well as in Reviews in Antiviral Therapy & Infectious Diseases.

Mascolini has published interviews with scores of leading HIV investigators, including Bernard Branson, Myron Cohen, Kevin DeCock, Anthony Fauci, Robert Grant, David Ho, Daniel Kuritzkes, Joep Lange and Mark Wainberg.

Categories Covered:People Over 50, Bone Problems and HIV, HIV Treatment and Medical Care, Sustiva (Efavirenz, Stocrin), Women, Physical Health Issues, Living Well With HIV, Mental Health, Starting HIV Treatment and Medical Care, Gay Men, Emtriva (Emtricitabine, FTC), Symtuza (Cobicistat/Darunavir/Emtricitabine/Tenofovir Alafenamide), Cancer and HIV, Conceiving and Having a Baby, Regional/Global Anti-HIV Efforts

Latest by Mark Mascolini

Higher Diabetes Rate in People With HIV Highlights Importance of Prevention and Monitoring

The diabetes rate is about 4% higher in people with HIV than in the general U.S. population -- highlighting the importance of early monitoring for and prevention of diabetes.

By Mark Mascolini

Heavy Alcohol Drinking Linked to Worse HIV Disease in U.S. Veterans

We already know some of the dangers of drinking too much alcohol, but new research suggests that heavy alcohol consumption exacerbates the negative effects of HIV in people living with the virus.

By Mark Mascolini

Study Highlights the Importance of Regular Anal Cancer Screenings in Gay Men With HIV, Even After Treatment

Half of HIV-positive gay or bisexual men successfully treated for anal lesions (tissue damage) that can lead to cancer had the same kind of lesions within 24 months, according to results of a recent study.

By Mark Mascolini

Chance of HIV Rebounding After Successful Treatment Steadily Declining

The chance of HIV rebounding after starting and maintaining antiretroviral therapy lies close to 1% per year in certain groups living with HIV, according to a study published in The Lancet HIV.

By Mark Mascolini

Heart Disease, Recent Cancer, Hepatitis C Raise Fracture Risk in People With HIV

Cardiovascular (heart) disease, a recent non-AIDS cancer and hepatitis C virus (HCV) infection each raised the risk of fracture (a broken bone) in a large study of people with HIV.

By Mark Mascolini

Heavy Alcohol Drinking Linked to Higher Death Risk Among People With HIV

Compared with moderate alcohol drinkers, people with self-reported or provider-reported heavy drinking ran a higher risk of death, according to a 10-year study.

By Mark Mascolini

Among Anti-HIV Drugs, Only Sustiva Has Possible Impact on Contraceptives

Most HIV drugs have little or no impact on the effectiveness of hormonal contraceptives, with the possible exception of Sustiva (efavirenz).

By Mark Mascolini

Rates of Starting Care and Treatment Rise Among HIV-Positive Gay and Bisexual Men

From 2008 through 2014, rates of entering HIV care and starting treatment rose significantly among gay and bisexual men in a 20-city study.

By Mark Mascolini

Fracture Risk Doubled in 50- to 59-Year-Old Men With HIV

Compared with a similar group of HIV-negative men, 50- to 59-year-old men with HIV in a large U.S. study had a doubled risk of fractured bones.

By Mark Mascolini

Prior Pneumonia, Smoking, and Drinking Explain Higher Lung Cancer Risk With HIV

A past pneumonia episode largely explained a higher risk of lung cancer in people living with HIV, according to a large study in California. Smoking and alcohol abuse also contributed to the higher risk.

By Mark Mascolini